FibroGen Inc reports results for the quarter ended June 30 - Earnings Summary

Kyntra Bio

11/08/2025 22:01

FibroGen Inc FGEN.OQ reported a quarterly adjusted loss of $1.88​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-4.00.  The mean expectation of two analysts for the quarter was for a loss of $2.30 per share. Wall Street expected results to range from $-5.62 to $1.01 per share.

Revenue fell 97.3% to $1.35 million from a year ago; analysts expected $2.63 million.

FibroGen Inc's reported EPS for the quarter was a loss of $1.88​.

The company reported a quarterly loss of $7.6 million.

FibroGen Inc shares had risen by 64.3% this quarter and lost 34.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 58.1% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for FibroGen Inc is $43.00, about 79.7% above its last closing price of $8.71

This summary was machine generated from LSEG data August 11 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-2.30
-1.88
Beat
Mar. 31 2025
0.50
1.25
Beat
Dec. 31 2024
-3.50
4.50
Beat
Sep. 30 2024
-7.62
-4.25
Beat